Key Developments: Quest Diagnostics Inc (DGX)

DGX on New York Consolidated

60.46USD
14 Aug 2014
Price Change (% chg)

$-1.29 (-2.10%)
Prev Close
$61.75
Open
$61.90
Day's High
$61.95
Day's Low
$60.29
Volume
1,827,504
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Latest Key Developments (Source: Significant Developments)

Quest Diagnostics Inc declares quarterly cash dividend
Friday, 15 Aug 2014 02:00pm EDT 

Quest Diagnostics Inc:Declares quarterly cash dividend of $0.33 per share.Payable on Oct. 22, 2014 to shareholders of record of Quest Diagnostics common stock on Oct. 07.  Full Article

Quest Diagnostics Inc narrows FY 2014 outlook in line with analysts' estimates
Thursday, 24 Jul 2014 07:04am EDT 

Quest Diagnostics Inc:Expects FY 2014 Revenues to increase 2.5-3.5 pct compared to FY 2013, versus previous guidance of up 2-4 pct.Expects FY 2014 adjusted diluted EPS to be between $4.00 and $4.10, versus previous guidance of between $3.95 and $4.15.Reported revenue of $7.146 bln in FY 2013.FY 2014 revenue of $7.346 bln and EPS of $4.02 - Thomson Reuters I/B/E/S.  Full Article

Sequenom Laboratories and Quest Diagnostics collaborate to expand patient access to the MaterniT21 PLUS Noninvasive Prenatal Test
Monday, 16 Jun 2014 08:00am EDT 

Sequenom Inc and Quest Diagnostics Inc:Announces an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21 PLUS laboratory-developed test.Quest expects to begin offering access to the test in the third quarter.Also Quest has formed a license agreement with Sequenom for certain NIPT patents and patent applications.License agreement is the first formed by Sequenom with a commercial lab in the United States.Quest intends to use the intellectual property for the purposes of developing and validating its own lab-developed NIPT test.  Full Article

Quest Diagnostics Inc declares quarterly cash dividend
Wednesday, 21 May 2014 02:12pm EDT 

Quest Diagnostics Inc:Declares quarterly cash dividend of $0.33 per share.Payable on July 23, 2014 to shareholders of record of Quest Diagnostics common stock on July 9, 2014.  Full Article

Quest Diagnostics Inc reaffirms FY 2014 guidance
Thursday, 24 Apr 2014 07:03am EDT 

Quest Diagnostics Inc:Says that FY 2014 revenue and adjusted earnings per diluted share guidance is unchanged.Expects FY 2014 revenues to increase 2 pct. to 4 pct. compared to prior year.Expects FY 2014 adjusted earnings per diluted share (EPS) to be between $3.95 and $4.15.Reported revenue of $7.146 bln in FY 2013.FY 2014 revenue of $7.322 bln and EPS of $4.04 - Thomson Reuters I/B/E/S.  Full Article

Quest Diagnostics Inc completes acquisition of Summit Health
Monday, 21 Apr 2014 09:11am EDT 

Quest Diagnostics Inc:Completes previously announced acquisition of Summit Health.Combined business will be referred to as Quest Diagnostics Health and Wellness Services.  Full Article

Quest Diagnostics Inc's focus diagnostics receives FDA clearance for moderate complexity simplexa HSV 1 & 2 Direct molecular test for aiding the diagnosis of encephalitis
Monday, 24 Mar 2014 09:12am EDT 

Quest Diagnostics Inc:Says its focus diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler.Encephalitis is an inflammation of the brain often caused by the herpes simplex or other viruses.  Full Article

Quest Diagnostics Inc issues senior notes due 2019 and 2024 - Form 8-K
Monday, 17 Mar 2014 04:57pm EDT 

Quest Diagnostics Inc:Issued $300,000,000 aggregate principal amount of 2.700pct Senior Notes due 2019 and $300,000,000 aggregate principal amount of 4.250pct Senior Notes due 2024.Notes to mature on Apr.1, 2019 and Apr. 1, 2024.Goldman, Sachs & Co., RBS Securities Inc., Wells Fargo Securities, LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC acts as the underwriters.  Full Article

Quest Diagnostics Inc to acquire Summit Health
Tuesday, 11 Mar 2014 07:00am EDT 

Quest Diagnostics Inc:Enters into a definitive purchase agreement under which Quest will acquire Summit Health.Terms of the transaction were not disclosed. Summit Health is a provider of on-site prevention and wellness programs primarily for employers.  Full Article

Quest Diagnostics Inc raises FY 2014 guidance
Monday, 10 Mar 2014 07:00am EDT 

Quest Diagnostics Inc:Expects FY 2014 revenues to increase 2-4 pct over FY 2013, versus the prior guidance of flat to down 2 pct.Expects FY 2014 adjusted earnings per diluted share to be between $3.95-$4.15, versus the prior guidance of between $3.90 and $4.10.Reported revenue of $7.146 billion in FY 2013.FY 2014 revenue of $7.214 billion and EPS of $4.03 - Thomson Reuters I/B/E/S.  Full Article

French biotechs court U.S. investors amid wave of IPOs

PARIS - Eighteen French biotech firms, several newly listed on the Paris stock market, head to New York on Wednesday and Thursday to convince U.S. investors to help fund the next stages of their research and development.

Search Stocks